The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
July 21, 2025
View Complete Issue         Table of Contents 2019 
Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)
July 21, 2025 (Issue: 1733)
Prademagene zamikeracel (Zevaskyn – Abeona Therapeutics), an autologous cell sheet-based gene therapy, has been approved by the FDA for treatment of wounds in patients with recessive dystrophic epidermolysis bullosa. It is the first autologous...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Prademagene Zamikeracel (Zevaskyn) for Recessive Dystrophic Epidermolysis Bullosa (online only)
Article code: 1733l
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.